Chromocell Therapeutics Corporation (CHRO)
NYSEAMERICAN: CHRO · IEX Real-Time Price · USD
2.010
-0.100 (-4.74%)
May 16, 2024, 4:00 PM EDT - Market closed
Company Description
Chromocell Therapeutics Corporation, a clinical-stage biotech company, focuses on the development and commercialization of new therapeutics to alleviate pain.
The company intends to selectively target the sodium ion-channel known as NaV1.7, as well as other receptors in the NaV family.
Its lead compound comprises CC8464, which is in Phase 2a clinical trials for use in the treatment of erythromelalgia, as well as other fields of neuropathic pain and acute and chronic eye pain.
Chromocell Therapeutics Corporation was founded in 2002 and is based in Freehold, New Jersey.
Chromocell Therapeutics Corporation
| Country | United States |
| Founded | 2002 |
| IPO Date | Feb 16, 2024 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 4 |
| CEO | Francis Knuettel II, M.B.A. |
Contact Details
Address: 685 Us Highway One North Brunswick, New Jersey 08902 United States | |
| Phone | (917) 644-6313 |
| Website | chromocell.com |
Stock Details
| Ticker Symbol | CHRO |
| Exchange | NYSEAMERICAN |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $6.00 |
| CIK Code | 0001919246 |
| Employer ID | 86-3335449 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Francis Knuettel II, M.B.A. | Chief Executive Officer, Chief Financial Officer, Treasurer and Secretary |
| Dr. Eric Lang M.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 15, 2024 | 424B3 | Prospectus |
| May 15, 2024 | 424B3 | Prospectus |
| May 15, 2024 | 10-Q | Quarterly Report |
| Apr 17, 2024 | POS EX | Filing |
| Apr 17, 2024 | 424B3 | Prospectus |
| Apr 17, 2024 | 424B3 | Prospectus |
| Apr 16, 2024 | 10-K | Annual Report |
| Apr 15, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Apr 9, 2024 | 8-K | Current Report |
| Apr 1, 2024 | NT 10-K | Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 |